JP2014529408A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014529408A5 JP2014529408A5 JP2014528860A JP2014528860A JP2014529408A5 JP 2014529408 A5 JP2014529408 A5 JP 2014529408A5 JP 2014528860 A JP2014528860 A JP 2014528860A JP 2014528860 A JP2014528860 A JP 2014528860A JP 2014529408 A5 JP2014529408 A5 JP 2014529408A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- medicament according
- hyperalgesia
- group
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 claims 30
- 208000004454 Hyperalgesia Diseases 0.000 claims 23
- 208000035154 Hyperesthesia Diseases 0.000 claims 12
- 210000004027 cell Anatomy 0.000 claims 12
- 125000003275 alpha amino acid group Chemical group 0.000 claims 10
- 238000001415 gene therapy Methods 0.000 claims 9
- 239000013598 vector Substances 0.000 claims 9
- 206010053552 allodynia Diseases 0.000 claims 7
- 238000000034 method Methods 0.000 claims 7
- 150000007523 nucleic acids Chemical class 0.000 claims 7
- 229920001184 polypeptide Polymers 0.000 claims 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims 7
- 102000004196 processed proteins & peptides Human genes 0.000 claims 7
- 208000002193 Pain Diseases 0.000 claims 6
- 108020004707 nucleic acids Proteins 0.000 claims 6
- 102000039446 nucleic acids Human genes 0.000 claims 6
- 208000004983 Phantom Limb Diseases 0.000 claims 5
- 206010056238 Phantom pain Diseases 0.000 claims 5
- 239000002773 nucleotide Substances 0.000 claims 5
- 125000003729 nucleotide group Chemical group 0.000 claims 5
- 230000002269 spontaneous effect Effects 0.000 claims 5
- 235000001014 amino acid Nutrition 0.000 claims 4
- 239000002775 capsule Substances 0.000 claims 4
- 150000001413 amino acids Chemical class 0.000 claims 3
- 239000012634 fragment Substances 0.000 claims 3
- 239000012528 membrane Substances 0.000 claims 3
- 101001034286 Homo sapiens Meteorin-like protein Proteins 0.000 claims 2
- 102100039669 Meteorin-like protein Human genes 0.000 claims 2
- 241000288906 Primates Species 0.000 claims 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims 2
- 241000687919 Rodinia Species 0.000 claims 2
- 230000000975 bioactive effect Effects 0.000 claims 2
- 235000018417 cysteine Nutrition 0.000 claims 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 2
- 230000002518 glial effect Effects 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 210000000130 stem cell Anatomy 0.000 claims 2
- 239000007929 subcutaneous injection Substances 0.000 claims 2
- 238000010254 subcutaneous injection Methods 0.000 claims 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- 241000710929 Alphavirus Species 0.000 claims 1
- 241000701822 Bovine papillomavirus Species 0.000 claims 1
- 241000711573 Coronaviridae Species 0.000 claims 1
- 241000702421 Dependoparvovirus Species 0.000 claims 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 102000010292 Peptide Elongation Factor 1 Human genes 0.000 claims 1
- 108010077524 Peptide Elongation Factor 1 Proteins 0.000 claims 1
- 206010036376 Postherpetic Neuralgia Diseases 0.000 claims 1
- 208000008765 Sciatica Diseases 0.000 claims 1
- 230000001618 algogenic effect Effects 0.000 claims 1
- 210000001130 astrocyte Anatomy 0.000 claims 1
- 230000037396 body weight Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000003203 everyday effect Effects 0.000 claims 1
- 230000001605 fetal effect Effects 0.000 claims 1
- 210000002950 fibroblast Anatomy 0.000 claims 1
- 210000005260 human cell Anatomy 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 238000007913 intrathecal administration Methods 0.000 claims 1
- 238000010253 intravenous injection Methods 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 210000001161 mammalian embryo Anatomy 0.000 claims 1
- 239000011159 matrix material Substances 0.000 claims 1
- 210000005155 neural progenitor cell Anatomy 0.000 claims 1
- 210000001178 neural stem cell Anatomy 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229960003387 progesterone Drugs 0.000 claims 1
- 239000000186 progesterone Substances 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims 1
- 210000000844 retinal pigment epithelial cell Anatomy 0.000 claims 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims 1
- 229960002930 sirolimus Drugs 0.000 claims 1
- 241000701161 unidentified adenovirus Species 0.000 claims 1
- 241000701447 unidentified baculovirus Species 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161531024P | 2011-09-05 | 2011-09-05 | |
| US61/531,024 | 2011-09-05 | ||
| PCT/DK2012/050330 WO2013034157A1 (en) | 2011-09-05 | 2012-09-05 | Treatment of allodynia, hyperalgsia, spontaneous pain, and phantom pain |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014529408A JP2014529408A (ja) | 2014-11-13 |
| JP2014529408A5 true JP2014529408A5 (enExample) | 2015-11-05 |
| JP6145667B2 JP6145667B2 (ja) | 2017-06-14 |
Family
ID=46940179
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014528860A Active JP6145667B2 (ja) | 2011-09-05 | 2012-09-05 | アロディニア、痛覚過敏、自発痛、及び幻痛の治療 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US9474786B2 (enExample) |
| EP (1) | EP2753347B1 (enExample) |
| JP (1) | JP6145667B2 (enExample) |
| KR (1) | KR102075881B1 (enExample) |
| CN (2) | CN107596346A (enExample) |
| AU (1) | AU2012306810B2 (enExample) |
| CA (1) | CA2846511C (enExample) |
| WO (1) | WO2013034157A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010009732A1 (en) | 2008-07-24 | 2010-01-28 | Nsgene A/S | Therapeutic use of a growth factor, metrnl |
| JP7140353B2 (ja) * | 2017-12-29 | 2022-09-22 | ヘリックスミス カンパニー， リミテッド | ハイブリッドｈｇｆ遺伝子が導入されたａａｖ（アデノ－関連ウイルス）ベクター |
| CN110004223A (zh) * | 2019-05-09 | 2019-07-12 | 苏州大学附属第一医院 | 一种用于预测早发型子痫前期发病的检测试剂盒 |
| JP2024518433A (ja) * | 2021-05-06 | 2024-05-01 | ホバ セラピューティクス エーピーエス | 化学療法誘発性神経障害性疼痛の予防及び治療 |
| KR20240118796A (ko) * | 2021-12-10 | 2024-08-05 | 호바 세라퓨틱스 에이피에스 | 침해수용성 통증의 치료 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4407957A (en) | 1981-03-13 | 1983-10-04 | Damon Corporation | Reversible microencapsulation of a core material |
| DE3681787D1 (de) | 1985-07-05 | 1991-11-07 | Whitehead Biomedical Inst | Expression von fremdem genetischem material in epithelzellen. |
| HK1008049A1 (en) | 1987-09-11 | 1999-04-30 | Whitehead Institute For Biomedical Research | Transduced fibroblasts and use therefor |
| US4892538A (en) | 1987-11-17 | 1990-01-09 | Brown University Research Foundation | In vivo delivery of neurotransmitters by implanted, encapsulated cells |
| US5156844A (en) | 1987-11-17 | 1992-10-20 | Brown University Research Foundation | Neurological therapy system |
| US5283187A (en) | 1987-11-17 | 1994-02-01 | Brown University Research Foundation | Cell culture-containing tubular capsule produced by co-extrusion |
| US5106627A (en) | 1987-11-17 | 1992-04-21 | Brown University Research Foundation | Neurological therapy devices |
| US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
| US5219990A (en) | 1991-01-28 | 1993-06-15 | Biogen, Inc. | Papillomavirus e2 trans-activation repressors |
| SG47470A1 (en) | 1991-04-25 | 1998-04-17 | Univ Brown Res Found | Implantable biocompatible immunoisolatory vehicle for delivery of a selected therapeutic products |
| PT639225E (pt) | 1992-04-30 | 2003-03-31 | Innogenetics Nv | Polipeptidos e peptidos novos acidos nucleicos que codificam para aqueles e sua utilizacao na area da terapia tumoral inflamacao ou imunologia |
| ES2178654T3 (es) | 1993-08-12 | 2003-01-01 | Neurotech Sa | Capsulas biocompatibles inmonoaisladoras que contienen celulas geneticamente alteradas para el suministro de moleculas biologicamente activas. |
| US5550050A (en) | 1994-04-15 | 1996-08-27 | Cytotherapeutics, Inc. | Method for implanting encapsulated cells in a host |
| US5677158A (en) | 1995-06-07 | 1997-10-14 | Research Foundation Of State University Of New York | In vitro packaging of adeno-associated virus DNA |
| US5904144A (en) | 1996-03-22 | 1999-05-18 | Cytotherapeutics, Inc. | Method for treating ophthalmic diseases |
| US6027721A (en) | 1996-05-20 | 2000-02-22 | Cytotherapeutics, Inc. | Device and method for encapsulated gene therapy |
| US6683058B1 (en) | 1998-04-15 | 2004-01-27 | Regents Of The University Of California | Methods for therapy of neurodegenerative disease of the brain |
| CA2329259C (en) | 1998-05-27 | 2003-08-05 | Avigen, Inc. | Convection-enhanced delivery of aav vectors |
| WO2001083510A1 (en) | 2000-05-02 | 2001-11-08 | Human Genome Sciences, Inc. | 29 human secreted proteins |
| EP1225224A4 (en) | 1999-10-01 | 2004-03-24 | Kyowa Hakko Kogyo Kk | DNA THE SHEAR RESPONSE |
| AU1395801A (en) | 1999-11-30 | 2001-06-12 | Innogenetics N.V. | New uses of suppressive macrophage activation factors |
| CA2395676A1 (en) | 2000-01-31 | 2001-08-02 | Human Genome Sciences, Inc. | Nucleic acids, proteins, and antibodies |
| WO2001055448A1 (en) | 2000-01-31 | 2001-08-02 | Human Genome Sciences, Inc. | Nucleic acids, proteins, and antibodies |
| AU2001234944A1 (en) | 2000-02-03 | 2001-08-14 | Hyseq, Inc. | Novel nucleic acids and polypeptides |
| ES2374971T3 (es) | 2001-03-28 | 2012-02-23 | Biogen Idec Ma Inc. | Uso de polipéptidos de neublastina para el tratamiento del dolor neuropático. |
| US20050208062A1 (en) | 2001-12-21 | 2005-09-22 | Yongming Sun | Compositions and methods relating to hepatic specific genes and proteins |
| WO2004035732A2 (en) | 2002-08-29 | 2004-04-29 | Five Prime Therapeutics, Inc. | Human polypeptides encoded by polynucleotides and methods of their use |
| WO2004079014A2 (en) | 2003-03-04 | 2004-09-16 | Arcturus Bioscience, Inc. | Signatures of er status in breast cancer |
| AU2005229434B2 (en) | 2004-03-30 | 2010-09-30 | Nsgene A/S | Therapeutic use of a growth factor, NsG33 |
| WO2006110593A2 (en) | 2005-04-07 | 2006-10-19 | Macrogenics, Inc. | Biological targets for the diagnosis, treatment and prevention of cancer |
| CN1982454A (zh) * | 2005-12-15 | 2007-06-20 | 中国医学科学院北京协和医院 | 一种骨质疏松相关基因及其编码蛋白和用途 |
| TWI501774B (zh) | 2006-02-27 | 2015-10-01 | Biogen Idec Inc | 神經性病症之治療 |
| WO2010009732A1 (en) * | 2008-07-24 | 2010-01-28 | Nsgene A/S | Therapeutic use of a growth factor, metrnl |
| JP6149226B2 (ja) | 2010-10-01 | 2017-06-21 | ホーバ セラピューティクス アンパルトセルスカブ | アロディニア、痛覚過敏、自発痛及び幻肢痛の処置 |
-
2012
- 2012-09-05 WO PCT/DK2012/050330 patent/WO2013034157A1/en not_active Ceased
- 2012-09-05 JP JP2014528860A patent/JP6145667B2/ja active Active
- 2012-09-05 US US14/241,568 patent/US9474786B2/en active Active
- 2012-09-05 AU AU2012306810A patent/AU2012306810B2/en active Active
- 2012-09-05 CN CN201710826364.9A patent/CN107596346A/zh active Pending
- 2012-09-05 CN CN201280054226.9A patent/CN104105501B/zh active Active
- 2012-09-05 CA CA2846511A patent/CA2846511C/en active Active
- 2012-09-05 KR KR1020147008926A patent/KR102075881B1/ko active Active
- 2012-09-05 EP EP12766380.5A patent/EP2753347B1/en active Active
-
2016
- 2016-09-27 US US15/277,698 patent/US9861682B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20200325200A1 (en) | Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15) | |
| TWI581801B (zh) | 治療血管新生相關之眼疾之組合物及方法 | |
| Layman et al. | Co-delivery of FGF-2 and G-CSF from gelatin-based hydrogels as angiogenic therapy in a murine critical limb ischemic model | |
| CN110831960A (zh) | C末端的cdnf和manf片段、包含它们的药物组合物及其用途 | |
| JP2013543378A5 (enExample) | ||
| US9474792B2 (en) | Method of treating metabolic disorders using PLA2G12A polypeptides and PLA2G12A mutant polypeptides | |
| EP3319623A1 (en) | Norrin regulation of junction proteins and the use thereof to treat epithelial or endothelial membrane leakage induced edema | |
| EP3302526A1 (en) | Norrin regulation of cellular production of junction proteins and use to treat retinal vasculature edema | |
| AU2015336008B2 (en) | Promoting epithelial regeneration post tonsillectomy using heparin binding epidermal growth factor like growth factor | |
| CA3171266A1 (en) | Norrin regulation of plasmalemma vesicle-associated protein and use to treat macular degeneration | |
| US9636364B2 (en) | Methods for treating ocular contusion and blunt injury and traumatic injury to the optic nerve | |
| Rykalina et al. | Intranasal human recombinant modified glucagon-like peptide-1: high antihyperglycemic activity and duration of action in mice | |
| US20240218033A1 (en) | Prevention and treatment of chemotherapy-induced neuropathic pain | |
| JP2026503094A (ja) | 安定化エングレイルドタンパク質水性組成物 | |
| WO2004105787A1 (en) | Methods of using combinations of egf-2 and egf-20 to treat central nervous system disorders | |
| CA3239550A1 (en) | Treatment of nociceptive pain | |
| JP2011084569A (ja) | プロサポシン受容体活性を刺激する方法 | |
| KR20230047329A (ko) | 졸중을 치료하기 위한 방법 및 조성물 | |
| WO2019231860A1 (en) | Method for treating or preventing radiotherapy- and chemotherapy-associated oral mucositis using locally administered heparin binding epidermal growth factor like growth factor (hb-egf) | |
| WO2017075661A1 (en) | Methods and compositions for treating cns injury |